Advanced search
Publication Cover
Journal of Chemotherapy Volume 18, 2006 - Issue 6
Submit an article Journal homepage
15
Views
3
CrossRef citations to date
0
Altmetric
Anticancer Chemotherapy

Retrospective Comparison of Chemotherapy-Induced Myelotoxicity in Patients with Ovarian Cancer Under and Over 60 Years of Age

F. Peintinger
,
A. Georgoulopoulos
,
G. Ralph
&
C. Piswanger
Pages 656-661 | Published online: 18 Jul 2013

References

  • http://seer.cancer.gov/csr/19752000/resultsmerged/sect20ovary.pdf
  • http://www-dep.iarc.fr/eucan.htm
  • National Comprehensive Cancer Network, Clinical prac-tice guidelines in oncology-v.1. 2005: 101-102.
  • Vasey PA, Jayson GC, Gordon A et al. Phase III ran-domized trial of docetaxel-carboplatin versus paclitaxel-carbo-platin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682–1691.
  • Ozols RF. Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 2000; 10: 33–37.
  • Muggia FM, Braly PS, Brady MF et al: Phase III ran-domized study of cisplatin versus paclitaxel in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106–115.
  • Du Bois A, Lueck HJ, Meier W et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as firstline treatment in ovarian cancer. J Natl Cancer Inst 2003; 95: 1320–1329.
  • McGuire WP III and Markman M. Primary ovarian can-cer chemotherapy: current standard of care. Br J Cancer 2003; 89: S3–S8.
  • Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group Studies. Cancer 1993; 71: 615–617.
  • Balducci L, Hardy CL, Lyman GH: Hemopoietic reserve in the older cancer patient: Clinical and economical considerations. Cancer Control 2000; 7: 539–547.
  • DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863–871.
  • Harter P, du Bois A, Schade-Brittinger C et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 2005; 16: 1801–1805.
  • Markman M, Lewis JL Jr, Saigo P et al. Epithelial ovar-ian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center Experience. Cancer 1993; 71: 634–637.
  • Oriel LG, Hartenbach EM, Remington OL. Trends in United States ovarian cancer mortality, 1979-1995. Obstet Gynecol 1999; 93: 30–33.
  • Hershman D, Jacobson JS, McBride R et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 2004; 94: 540–549.
  • Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005; 11: 461–473.
  • Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580–1584.
  • Giovanazzi-Bannon S, Radermaker A, Lai G et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials; an Illinois Cancer Center Study. J ClinOncol 1994; 12: 2447–2452.
  • Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovari-an cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 94: 368–374.
  • Maas HAAM, Kruitwagen RFPM, Lemmens VEPP, Goey SH, Janssen-Heijnen MLG. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 2005; 97: 104–109.
  • Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: A population-based study. J Clin Oncol 2003; 21: 1530–1535.
  • Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993; 49: 86–91.
  • Higgins RV, Naumann RW, Gardner J, Hall JB. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol Oncol 1999; 75: 464–467.
  • Villella JA, Chaudhry T, Pearl ML et al. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 2002; 86: 316–322.
  • Bruchim I, Altaras M, Fishman A. Age contrasts in clin-ical characteristics and pattern of care in patients with epithe-lial ovarian cancer. Gynecol Oncol 2002; 86: 274–8.
  • Petignat P, Fioretta G, Verkooijen HM et al. Poorer survival of elderly patients with ovarian cancer: A population-based study. Surg Oncol 2004; 13: 181–186.
  • Thigpen T, Brady MF, Omura GA et al. Age as a prog-nostic factor in ovarian cancer. The Gynecologic Oncology Group experience. Cancer 1993;71 (Suppl. 2):606-614.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.